View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 17, 2020updated 25 Nov 2021 10:47am

Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule

Merck (MSD) has completed its previously announced acquisition of US-based biopharmaceutical company ArQule. 

Merck (MSD) has completed its previously announced acquisition of US-based biopharmaceutical company ArQule.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

The $2.7bn deal closed following completion of the cash tender offer that involved acquiring ArQule ’s outstanding shares of common stock at $20 per share.

As agreed, a Merck unit merged with and into ArQule , which will now operate as a wholly owned subsidiary of Merck.

The deal completed more than a month after the two companies entered a definitive agreement to execute the merger.

ArQule is engaged in the development of kinase inhibitor therapies for cancer and other rare diseases. The acquisition strengthens Merck’s oncology pipeline with the addition of potential drug candidates from ArQule .

Overall, ArQule ’s clinical-stage pipeline comprises four drug candidates under various stages of development.

It includes its lead candidate ARQ 531, an investigational, oral Bruton’s tyrosine kinase (BTK) inhibitor to treat B-cell malignancies.

At the time of the deal announcement, Merck Research Laboratories president Roger Perlmutter said: “ArQule ’s focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties.

“This acquisition strengthens Merck’s pipeline with the addition of these strategic assets including, most notably, ARQ 531, a compelling candidate for the treatment of B-cell malignancies.”

Headquartered in New Jersey, Merck is a global biopharmaceutical firm with operations in 140 countries.

Last month, the company secured the US Food and Drug Administration (FDA) approval for its Ervebo vaccine to prevent Ebola virus disease (EVD).

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology